Elutia Inc. has completed the sale of its BioEnvelope business, including the EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation for $88 million in cash. With the transaction finalized, Elutia will focus on advancing its NXT-41x drug-eluting biomatrix platform, aimed at reducing reconstruction infections following mastectomy. The company plans to bring NXT-41x to market in the first half of 2027, targeting the $1.5 billion U.S. breast reconstruction biologics market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elutia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-097561), on October 07, 2025, and is solely responsible for the information contained therein.